HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Submit a response Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schackman, B. R. Articles by Freedberg, K. A. Search for Related Content PubMed PubMed Citation Articles by Schackman, B. R. Articles by Freedberg, K. A. Related Collections Health Care Facilities/Services Insurance Other Health Financing HIV/AIDS

Bruce R. Schackman, PhD, Sue J. Goldie, MD, MPH, Milton C. Weinstein, PhD, Elena Losina, PhD, Hong Zhang, SM and Kenneth A. Freedberg, MD, MSc

At the time of the study Bruce R. Schackman was, and Sue J. Goldie, Milton C. Weinstein, and Kenneth A. Freedberg are now, with the Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass. Elena Losina and Dr. Freedberg are with the Department of Epidemiology and Biostatistics, Boston University School of Public Health, Boston. Dr. Losina, Hong Zhang, and Dr. Freedberg are with the Division of General Medicine and Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, Boston.

Correspondence: Requests for reprints should be sent to Bruce R. Schackman, PhD, Department of Public Health, Weill Medical College of Cornell University, 411 East 69th St, New York, NY 10021 (e-mail: brs2006{at}med.cornell.edu).

Objectives. This study was designed to examine the societal cost-effectiveness and the impact on government payers of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults.

Methods. A state-transition simulation model of HIV disease was used. Data were derived from the Multicenter AIDS Cohort Study, published randomized trials, and medical care cost estimates for all government payers and for Massachusetts, New York, and Florida.

Results. Quality-adjusted life expectancy increased from 7.64 years with therapy initiated at 200 CD4 cells/µL to 8.21 years with therapy initiated at 500 CD4 cells/µL. Initiating therapy at 500 CD4/µL was a more efficient use of resources than initiating therapy at 200 CD4/µL and had an incremental cost-effectiveness ratio of $17 300 per quality-adjusted life-year gained, compared with no therapy. Costs to state payers in the first 5 years ranged from $5500 to $24 900 because of differences among the states in the availability of federal funds for AIDS drug assistance programs.

Conclusions. Antiretroviral therapy initiated at 500 CD4 cells/µL is cost-effective from a societal perspective compared with therapy initiated later. States should consider Medicaid waivers to expand access to early therapy.

This article has been cited by other articles:

				J. Hornberger, M. Holodniy, K. Robertus, M. Winnike, E. Gibson, and E. Verhulst A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy Med Decis Making, December 1, 2007; 27(6): 789 - 821. [Abstract] [PDF]

				E. M. Howell, R. B. Greifinger, and A. S. Sommers What Is Known About the Cost-Effectiveness of Health Services for Returning Prisoners? Journal of Correctional Health Care, April 1, 2004; 10(3): 399 - 436. [Abstract] [PDF]

				J. M. Mrus and J. Tsevat Cost-Effectiveness of Interventions to Reduce Vertical HIV Transmission from Pregnant Women Who Have Not Received Prenatal Care Med Decis Making, January 1, 2004; 24(1): 30 - 39. [Abstract] [PDF]

				J. M. Mrus, M. S. Yi, K. A. Freedberg, A. W. Wu, R. Zackin, H. Gorski, and J. Tsevat Utilities Derived from Visual Analog Scale Scores in Patients with HIV/AIDS Med Decis Making, September 1, 2003; 23(5): 414 - 421. [Abstract] [PDF]